Items Tagged ‘HDACs’

August 9th, 2016

Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia


The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML). Acute myeloid leukemia (AML) is a cancer of the bone marrow (spongy portion found in the middle of bones) and blood […]

View full entry

Tags: Acute Myeloid Leukemia, AML, azacitidine, Breakthrough Therapy Designation, elderly, FDA. BTD, HDACs, Leukemia, News, Pracinostat